Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center:A retrospective observational cohort study  

作　　者：Natália Souza Nunes Siqueira Livia Bitencourt Pascoal Bruno Lima Rodrigues Marina Moreira de Castro Alan Sidnei Corrêa Martins Dante Orsetti Silva Araújo Luis Eduardo Miani Gomes Michel Gardere Camargo Maria de Lourdes Setsuko Ayrizono Raquel Franco Leal 

机构地区：[1]Inflammatory Bowel Disease Research Laboratory,Gastrocenter,Colorectal Surgery Unit,School of Medical Sciences,University of Campinas(Unicamp),Campinas 13083-878,São Paulo,Brazil

出　　处：《World Journal of Clinical Cases》2023年第12期2740-2752,共13页世界临床病例杂志

基　　金：Supported by the National Council for Scientific and Technological Development(CNPq),No.302557/2021-0(to Leal RF);the Brazilian Coordination for the Improvement of Higher Education Personnel[CAPES(Coordenação de Aperfeiçoamento de Pessoal de Nível Superior),Brazil],No.001(to Siqueira NSN),the São Paulo Research Foundation(FAPESP),No.2021/02997-9(to D.O.S.A.).

摘　　要：BACKGROUND Although the gastrointestinal tract is the most affected by Crohn’s disease(CD),the condition triggers other consequent manifestations,and iron deficiency anemia(IDA)is one of the most common.Intravenous(IV)iron replacement is currently available through several drugs,such as ferric hydroxide sucrose and ferric carboxymaltose(FCM).However,the clinical management of these conditions can be challenging.AIM To elucidate the drug’s effectiveness,the present study analyzed,through medical records,the clinical and epidemiological data of a cohort of patients with active CD who received IV FCM for the IDA treatment.METHODS This retrospective observational study included 25 patients with active CD,severe anemia,and refractory to previous conventional treatments.Patients were evaluated two times:During the last treatment with ferric hydroxide sucrose and treatment with FCM.RESULTS After treatment with FCM,parameters of IDA assessment significantly improved,serum hemoglobin(Hb)levels increased in 93%of patients(P<0.0001),and in 44%,there was an increase of≥2 g/dL in a single application.In addition,86%of the patients showed an increase in serum iron(P<0.0001)and ferritin(P=0.0008)and 50%in transferrin saturation(P=0.01).The serum iron levels at baseline showed a negative association with the ileal and colonic CD and use of biologics and a positive association with patients who developed CD later in life after the age of 40(A3)and with a stenosing(B2)and fistulizing(B3)phenotype.The values of Hb and hematocrit after ferric hydroxide sucrose treatment remained similar to those found before treatment.CONCLUSION This study demonstrated that FCM is an important therapeutic strategy for treating IDA in CD patients,achieving satisfactory results in refractory cases.

关 键 词：Ferric carboxymaltose Iron deficiency anemia Crohn’s disease Inflammatory bowel disease ANEMIA Clinical management 

分 类 号：R574.62[医药卫生—消化系统] R556[医药卫生—内科学]